Table 1 Clinical and laboratory characteristics of 60 adults with acute myeloid leukemia
From: Prognostic value of CIP2A gene expression in adult Egyptian acute myeloid leukemia patients
Parameter | Value (mean ± SD) or distribution (n (%)) |
|---|---|
Age (years) | 36.8 ± 1.6 |
Gender | |
 Male | 27 (45.0) |
 Female | 33 (55.0) |
Hepatomegaly | 25 (41.6) |
Splenomegaly | 23 (38.3) |
Lymphadenopathy | 12 (20.0) |
Total leukocytic count (× 109/L) | 49.8 ± 7.6 |
Hemoglobin (g/dL) | 8.1 ± 0.2 |
Platelets (× 109/L) | 56.7 ± 9.8 |
Peripheral-blood blasts (%) | 50.4 ± 26.4 |
Bone-marrow blasts (%) | 62.3 ± 20.7 |
Bone-marrow cellularitya | |
 Normocellular | 9 (15.0) |
 Hypercellular | 51 (85.0) |
Cytogenetics and molecular classification | |
 Normal karyotype | 9 (15.0) |
t(5:17) | 6 (10.0) |
t(8;21) | 6 (10.0) |
t(9;12) | 5 (8.3) |
 Trisomy 21 | 2 (3.3) |
 Inversion 16 | 1 (1.7) |
 Trisomy 3 | 1 (1.7) |
Multiple | 9 (15.0) |
Cytogenetics not performed | 21 (35.0) |
FLT3 status | |
 Wild type | 51 (85.0) |
 Mutant | 9 (15.0) |
French–American–British classification | |
 M1 | 7 (11.7) |
 M2 | 20 (33.3) |
 M3 | 5 (8.3) |
 M4 | 14 (23.3) |
 M5a | 4 (6.7) |
 M7 | 1 (1.7) |
CD34 status | |
 Positive | 35 (58.3) |
 Negative | 25 (41.6) |